Profile data is unavailable for this security.
About the company
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
- Revenue in USD (TTM)128.45m
- Net income in USD5.71m
- Incorporated2007
- Employees524.00
- LocationLifecore Biomedical Inc3515 Lyman BoulevardCHASKA 55318United StatesUSA
- Phone+1 (952) 368-4300
- Fax+1 (302) 636-5454
- Websitehttps://www.lifecore.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Telomir Pharmaceuticals Inc | 0.00 | -22.96m | 132.36m | 1.00 | -- | 299.40 | -- | -- | -0.8145 | -0.8145 | 0.00 | 0.0149 | 0.00 | -- | -- | 0.00 | -721.99 | -- | -1,752.70 | -- | -- | -- | -- | -- | -- | -2.06 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Puma Biotechnology Inc | 243.57m | 23.24m | 142.35m | 185.00 | 6.11 | 2.00 | 4.09 | 0.5845 | 0.475 | 0.475 | 5.03 | 1.45 | 1.15 | 17.91 | 5.83 | 1,316,589.00 | 10.95 | -12.21 | 18.85 | -20.53 | 69.29 | 78.78 | 9.54 | -11.79 | 1.40 | 3.61 | 0.5234 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Elutia Inc | 24.78m | -60.29m | 152.07m | 54.00 | -- | -- | -- | 6.14 | -2.10 | -1.84 | 0.8695 | -1.16 | 0.4813 | 2.82 | 8.52 | 458,925.90 | -117.08 | -42.93 | -649.22 | -79.34 | 42.41 | 43.32 | -243.28 | -64.16 | 0.849 | -1.18 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| LifeVantage Corp | 196.01m | 4.13m | 164.83m | 217.00 | 41.23 | 5.93 | 21.71 | 0.8409 | 0.3192 | 0.3192 | 15.27 | 2.22 | 3.06 | 2.50 | 71.64 | 903,290.30 | 6.46 | 9.95 | 10.17 | 15.55 | 79.21 | 81.45 | 2.11 | 3.08 | 0.9923 | 559.36 | 0.00 | 26.95 | -6.20 | -2.40 | 15.63 | -16.94 | -2.18 | -- |
| Scpharmaceuticals Inc | 30.28m | -80.12m | 173.10m | 135.00 | -- | 5.64 | -- | 5.72 | -1.91 | -1.91 | 0.7417 | 0.6137 | 0.262 | 0.7268 | 4.52 | 224,281.50 | -69.31 | -38.23 | -78.18 | -42.31 | 69.72 | -- | -264.60 | -1,360.16 | 6.89 | -8.42 | 0.6246 | -- | -- | -- | -48.79 | -- | -- | -- |
| Mediwound Ltd | 20.14m | -19.97m | 180.78m | 100.00 | -- | 8.71 | -- | 8.98 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Inhibrx Biosciences Inc | 1.73m | 1.64bn | 202.37m | 166.00 | 0.117 | 1.13 | 0.123 | 116.71 | 119.47 | 119.47 | 0.0499 | 12.33 | 0.0058 | -- | 4.41 | 10,445.78 | 552.15 | -77.06 | 637.71 | -93.91 | -- | -- | 94,778.95 | -1,590.91 | -- | -45.76 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Biostem Technologies Inc | 210.39m | 14.32m | 219.71m | 67.00 | 21.41 | 9.65 | 15.11 | 1.04 | 0.6302 | 0.6302 | 10.58 | 1.40 | 3.82 | 8.46 | 5.01 | -- | 26.03 | -- | 135.75 | -- | 94.84 | -- | 6.81 | -- | 1.23 | 27.98 | 0.1576 | -- | -- | -- | -- | -- | -- | -- |
| Lifecore Biomedical Inc | 128.45m | 5.71m | 257.05m | 524.00 | 188.96 | -- | 17.86 | 2.00 | 0.0369 | 0.0595 | 3.82 | 1.28 | 0.5217 | 2.01 | 4.96 | 245,124.00 | 2.32 | -5.91 | 2.74 | -8.33 | 34.65 | 31.01 | 4.45 | -19.16 | 0.803 | 0.125 | 0.7641 | -- | 24.20 | -25.46 | 114.53 | 34.47 | -16.72 | -- |
| Precigen Inc | 3.96m | -139.56m | 257.82m | 202.00 | -- | 4.78 | -- | 65.06 | -0.5479 | -0.5479 | 0.0154 | 0.1891 | 0.0289 | -- | 5.40 | 19,618.81 | -101.81 | -31.50 | -126.84 | -38.63 | -12.44 | 44.00 | -3,521.68 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Eton Pharmaceuticals Inc | 34.68m | -5.48m | 277.74m | 30.00 | -- | 17.38 | -- | 8.01 | -0.2135 | -0.2135 | 1.34 | 0.6186 | 1.03 | 9.44 | 7.63 | 1,155,900.00 | -16.27 | -46.22 | -29.44 | -58.20 | 59.30 | 72.16 | -15.81 | -76.86 | 1.41 | -- | 0.2052 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Sanara Medtech Inc | 78.06m | -8.36m | 326.44m | 107.00 | -- | 8.20 | -- | 4.18 | -0.9871 | -0.9871 | 9.24 | 4.55 | 0.9518 | 1.91 | 8.39 | 729,503.40 | -10.33 | -17.73 | -12.37 | -22.07 | 90.16 | 88.08 | -10.86 | -17.13 | 2.02 | -3.44 | 0.4326 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Amylyx Pharmaceuticals Inc | 196.49m | -259.47m | 355.76m | 384.00 | -- | 1.81 | -- | 1.81 | -3.82 | -3.82 | 2.87 | 2.86 | 0.5479 | 2.56 | 12.64 | 511,679.70 | -72.35 | -- | -84.00 | -- | 78.88 | -- | -132.05 | -- | 4.55 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Lifecore Biomedical Inc's reporting currency: US Dollar USD
54.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wynnefield Capital, Inc.as of 03 Oct 2024 | 4.70m | 12.77% |
| Legion Partners Asset Management LLCas of 03 Oct 2024 | 4.40m | 11.96% |
| Greenhaven Road Investment Management LPas of 30 Sep 2024 | 2.23m | 6.05% |
| 22NW LPas of 30 Sep 2024 | 1.76m | 4.77% |
| David Capital Partners LLCas of 30 Sep 2024 | 1.66m | 4.49% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.39m | 3.78% |
| 325 Capital LLCas of 30 Sep 2024 | 1.37m | 3.72% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.29m | 3.51% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 656.63k | 1.78% |
| Geode Capital Management LLCas of 30 Sep 2024 | 597.69k | 1.62% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
